SCHEMBL1735671

SCHEMBL1735671

COC(=O)C(CO)NS(=O)(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
MMP2 P08253 8/20 0.48
MMP13 P45452 5/20 0.48
MMP3 P08254 3/20 0.48
MMP9 P14780 6/20 0.48
ADAMTS4 O75173 3/20 0.48
MMP8 P22894 2/20 0.47
MMP1 P03956 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CTSL P07711 1/20 0.46
CTSS P25774 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1737163 1.00 POLB (0.51) POLBMMP2MMP13MMP3MMP9
SCHEMBL10076124 0.88 POLB (0.51) POLBMMP2MMP13MMP9ADAMTS4
SCHEMBL8049244 0.86 ALDH1A1 (0.53) MMP2MMP13MMP3MMP9MMP8
SCHEMBL7315790 0.86 POLB (0.50) POLBMMP2MMP13MMP9ADAMTS4
SCHEMBL7397814 0.86 POLB (0.50) POLBMMP2MMP13MMP9ADAMTS4
SCHEMBL14514554 0.86 ALDH1A1 (0.53) MMP2MMP13MMP3MMP9MMP8
SCHEMBL31064911 0.86 POLB (0.50) POLBMMP2MMP13MMP9ADAMTS4
SCHEMBL31128480 0.86 ADAMTS4 (0.55) POLBMMP2MMP13MMP9ADAMTS4
SCHEMBL5639380 0.85 MMP2 (0.57) MMP2MMP13MMP3MMP9MMP8
Hydrochloric Acid SCHEMBL7315781 0.85 POLB (0.49) POLBMMP2MMP13MMP9ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 WO disclosed
EP-2142533-A1 IMIDAZOLIDINONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-01-13 EP disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 US disclosed
WO-2008119657-A1 IMIDAZOLIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 WO disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 POLB 3268/4885MMP2 4754/4885MMP13 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.